You are here: Industry Insights > EGFR

News List

Made-in-China New Drugs: The Game and Breakthrough in the Over - 4 - Billion Market Lezhi
September 05, 2025
Profiles 16 China-made blockbuster drugs exceeding ￥1B sales, highlighting intense PD-1 competition, EGFR tech innovation, and bispecific antibody/non-oncology surge.
Made-in-China New Drugs: Breaking Through the RMB 4-Billion Battlefield lezhi
September 05, 2025
In 2024, the "Billion-Yuan Club" of made-in-China first-in-class new drugs expanded to 16 members.
No Increase in Risk With Dapagliflozin in Patients With Stage 4 CKD drugs
July 22, 2021
For patients with stage 4 chronic kidney disease (CKD), a similar pattern of reduced kidney, cardiovascular, and mortality risks is seen with dapagliflozin versus placebo, with no evidence of increased risks.
Vela Diagnostics Announces Collaboration with the National Cancer Centre of Singapore to Refine Novel Cancer Therapy prnasia
June 04, 2021
Vela Diagnostics announced a collaboration with the National Cancer Centre of Singapore (NCCS) to develop a molecular diagnostic assay to predict individual patients' responses to a cancer therapy called Epidermal Growth Factor Receptor (EGFR) ...
Rybrevant Approved for NSCLC With EGFR Exon 20 Insertion Mutations drugs
May 26, 2021
Rybrevant (amivantamab-vmjw) was approved for adults with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, the U.S. Food and Drug Administration announced Friday.
Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis firstwordpharma
May 26, 2021
Travere Therapeutics, Inc. today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS).
FDA approves Janssen’s Rybrevant pharmatimes
May 25, 2021
The US Food and Drug Administration (FDA) has approved Janssen’s Rybrevant as the first treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S prnasia
April 07, 2021
Bridge Biotherapeutics Inc., a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor activity of BBT-176 in ...
Janssen Submits BLA for Metastatic Lung Cancer Treatment americanpharmaceuticalreview
December 24, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic ...
NICE backing for AZ' Tagrisso pharmatimes
September 15, 2020
AstraZeneca's Tagrisso (osimertinib) has been recommended for use within NHS England, in line with its licensed indication, for adults with untreated locally-advanced or metastatic epidermal growth factor receptor (EGFR) ...